BMY
Bristol-Myers Squibb Company
—
54 $
-1.2800 (%-2.32)
Previous Close: 55.28
Day Low₺53.44
Day High₺55.325
BMY: Bristol-Myers Squibb Company Financials
BMY Income Statement
Total revenue
Net income
Gross margin TTM
67.65%
Operating margin TTM
26.34%
Net profit margin TTM
14.63%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 48,194,000,000 | 48,300,000,000 | 45,006,000,000 | 46,159,000,000 |
| Operating income | 12,696,000,000 | 9,658,000,000 | 8,472,000,000 | 9,271,000,000 |
| Net income | 7,053,000,000 | -8,948,000,000 | 8,025,000,000 | 6,327,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 48,194,000,000 | 48,300,000,000 | 45,006,000,000 | 46,159,000,000 |
| Cost of revenue | 15,592,000,000 | 20,868,000,000 | 19,649,000,000 | 19,669,000,000 |
| Gross profit | 32,602,000,000 | 27,432,000,000 | 25,357,000,000 | 26,490,000,000 |
| Research and development expenses | 9,612,000,000 | 9,782,000,000 | 9,207,000,000 | 9,411,000,000 |
| General and administrative expenses | 5,660,000,000 | 6,365,000,000 | 0 | 0 |
| Selling and marketing expenses | 1,584,000,000 | 1,500,000,000 | 0 | 0 |
| Selling, general and administrative expenses | 7,244,000,000 | 7,865,000,000 | 7,678,000,000 | 7,808,000,000 |
| Other expenses | 3,050,000,000 | 127,000,000 | 0 | 0 |
| Operating expenses | 19,906,000,000 | 17,774,000,000 | 16,885,000,000 | 17,219,000,000 |
| Cost and expenses | 35,498,000,000 | 38,642,000,000 | 36,534,000,000 | 36,888,000,000 |
| Net interest income | -1,210,000,000 | -1,947,000,000 | -1,166,000,000 | -1,232,000,000 |
| Interest income | 300,000,000 | 0 | 0 | 0 |
| Interest expense | 1,510,000,000 | 1,947,000,000 | 1,166,000,000 | 1,232,000,000 |
| Depreciation and amortization | 3,860,000,000 | 9,600,000,000 | 9,760,000,000 | 10,276,000,000 |
| EBITDA | 14,545,000,000 | 3,168,000,000 | 19,366,000,000 | 19,221,000,000 |
| EBIT | 10,684,000,000 | -6,432,000,000 | 9,606,000,000 | 8,945,000,000 |
| Non-operating income (excl. interest) | 2,012,000,000 | 16,090,000,000 | -1,134,000,000 | 326,000,000 |
| Operating income | 12,696,000,000 | 9,658,000,000 | 8,472,000,000 | 9,271,000,000 |
| Total other income/expenses (net) | -3,368,000,000 | -18,037,000,000 | -32,000,000 | -1,558,000,000 |
| Income before tax | 9,328,000,000 | -8,379,000,000 | 8,440,000,000 | 7,713,000,000 |
| Income tax expense | 2,272,000,000 | 554,000,000 | 400,000,000 | 1,368,000,000 |
| Net income from continuing operations | 7,056,000,000 | -8,933,000,000 | 8,040,000,000 | 6,345,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 5,000,000 | 0 | 0 | 0 |
| Net income | 7,053,000,000 | -8,948,000,000 | 8,025,000,000 | 6,327,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 7,053,000,000 | -8,948,000,000 | 8,025,000,000 | 6,327,000,000 |
| EPS | 3 | -4 | 4 | 3 |
| Diluted EPS | 3 | -4 | 4 | 3 |
| Weighted average shares outstanding | 2,041,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 |
| Weighted average diluted shares outstanding | 2,041,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 |